INTRAHEPATIC CHOLANGIOCARCINOMA

This study tests a two-pronged chemotherapy approach for people with intrahepatic cholangiocarcinoma (a type of bile duct cancer) that cannot be removed by surgery. Participants receive chemotherapy directly to the liver through a surgically placed pump, plus standard chemotherap…

This Phase 2 trial tested a combination of three treatments—local chemotherapy delivered via beads into the liver, a targeted drug called apatinib, and an immunotherapy (PD-1 antibody)—in 20 patients with advanced bile duct cancer that had worsened after standard first-line chemo…

This study tested whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (gemcitabine/cisplatin) helps people with advanced bile duct or gallbladder cancer live longer. Over 1,000 participants received either the combination or chemo plus a placebo. The goal…

This study tested a combination of two experimental drugs, AK112 and AK117, with or without chemotherapy, in 154 people with advanced solid tumors. The goal was to see if the combo could shrink tumors and control the disease. The trial has finished, and researchers are now lookin…

This study tested a new oral drug called RLY-4008 in 490 adults with advanced bile duct cancer or other solid tumors that have specific FGFR2 gene changes. The drug is designed to block the FGFR2 protein, which can drive cancer growth. The trial aimed to find the safest dose and …

This study tested a drug called ZW25 (zanidatamab) in 87 people with advanced or metastatic HER2-amplified biliary tract cancer that had worsened after standard chemotherapy. The goal was to see if the drug could shrink tumors and how long that effect lasted. The trial is now com…

This study tested proton beam radiation, a highly targeted form of radiotherapy, in 83 people with liver cancer that could not be surgically removed. The goal was to see if this precise approach could control tumors while reducing damage to healthy tissue. Participants received d…

This study looked at whether a special ultrasound using gas microbubbles can predict how well bile duct cancer responds to targeted radiotherapy. The ultrasound can also pop these bubbles, which might make the cancer easier to treat. Sixteen adults with bile duct cancer took part…

This study looked at 120 adults with breast, pancreatic, or biliary cancer to see if a new 3D measurement method (TDTP-RECIST) is better than the standard way (RECIST 1.1) for tracking tumor shrinkage before surgery. Researchers compared imaging results with actual tumor tissue r…

This completed study used artificial intelligence to examine CT scans from 274 liver cancer patients who had already received radiation therapy. The goal was to find the radiation dose that causes a visible liver reaction, which could help doctors avoid liver injury in future tre…